Association of Zolpidem With Increased Mortality in Patients With Brain Cancer: A Retrospective Cohort Study Based on the National Health Insurance Service Database
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Zolpidem is one of the most common hypnotics prescribed to treat insomnia worldwide. However, there are numerous reports of a positive association between zolpidem and mortality, including an association with increased cancer-specific mortality found in a Taiwanese cohort study. This study aimed to determine the association between zolpidem use and brain-cancer-specific mortality in patients with brain cancer. Methods This population-based, retrospective cohort study analyzed data in the National Health Insurance Service database. All incident cases of brain cancer at an age of ≥18 years at the time of brain cancer diagnosis over a 15-year period (2003–2017) were included. A multivariate Cox regression analysis after adjustment for covariables was performed to evaluate the associations of zolpidem exposure with brain-cancer-specific and all-cause mortality. Results This study identified 38,037 incident cases of brain cancer, among whom 11,823 (31.1%) patients were exposed to zolpidem. In the multivariate Cox regression model, the brain-cancer-specific mortality rate was significantly higher in patients who were prescribed zolpidem than in those with no zolpidem prescription (adjusted hazard ratio [HR]=1.14, 95% confidence interval [CI]=1.08–1.21, p<0.001). Zolpidem exposure was significantly associated with increased brain-cancer-specific mortality after adjustment in younger adults (age 18– 64 years; adjusted HR=1.37, 95% CI=1.27–1.49) but not in older adults (age ≥65 years; adjusted HR=0.94, 95% CI=0.86–1.02). Conclusions Zolpidem exposure was significantly associated with increased brain-cancerspecific mortality in patients with brain cancer aged 18–64 years. Further prospective studies are warranted to understand the mechanism underlying the effect of zolpidem on mortality in patients with brain cancer.
Abstract
Background and Purpose Zolpidem is one of the most common hypnotics prescribed to treat insomnia worldwide. However, there are numerous reports of a positive association between zolpidem and mortality, including an association with increased cancer-specific mortality found in a Taiwanese cohort study. This study aimed to determine the association between zolpidem use and brain-cancer-specific mortality in patients with brain cancer. Methods This population-based, retrospective cohort study analyzed data in the National Health Insurance Service database. All incident cases of brain cancer at an age of ≥18 years at the time of brain cancer diagnosis over a 15-year period (2003–2017) were included. A multivariate Cox regression analysis after adjustment for covariables was performed to evaluate the associations of zolpidem exposure with brain-cancer-specific and all-cause mortality. Results This study identified 38,037 incident cases of brain cancer, among whom 11,823 (31.1%) patients were exposed to zolpidem. In the multivariate Cox regression model, the brain-cancer-specific mortality rate was significantly higher in patients who were prescribed zolpidem than in those with no zolpidem prescription (adjusted hazard ratio [HR]=1.14, 95% confidence interval [CI]=1.08–1.21, p<0.001). Zolpidem exposure was significantly associated with increased brain-cancer-specific mortality after adjustment in younger adults (age 18– 64 years; adjusted HR=1.37, 95% CI=1.27–1.49) but not in older adults (age ≥65 years; adjusted HR=0.94, 95% CI=0.86–1.02). Conclusions Zolpidem exposure was significantly associated with increased brain-cancerspecific mortality in patients with brain cancer aged 18–64 years. Further prospective studies are warranted to understand the mechanism underlying the effect of zolpidem on mortality in patients with brain cancer.
참고문헌 (21)
- Kripke DF, "Hypnotics’ association with mortality or cancer : a matched cohort study", BMJ Open, 2, pp.e000850~ (2012)
- Belleville G, "Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey", Can J Psychiatry, 55, pp.558~567 (2010)
- Choi JW, "Use of sedative-hypnotics and mortality : a population-based retrospective cohort study", J Clin Sleep Med, 14, pp.1669~1677 (2018)
- Linnet K, "Association between prescription of hypnotics", anxiolytics and mortality in multimorbid and non-multimorbid patients : a longitudinal cohort study in primary care, 2019, pp.9, e033545~
- Weich S, "Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards : retrospective cohort study", BMJ, 348, pp.g1996~ (2014)
- Hsiao FY, "Ten-year trend in prescriptions of zhypnotics among the elderly : a nationwide, cross-sectional study in Taiwan", J Clin Gerontol Geriatr, 4, pp.37~41 (2013)
- Yeon-Jung Lim, "Potentially Inappropriate Medications by Beers Criteria in Older Outpatients: Prevalence and Risk Factors", Korean Journal of Family Medicine, 37(6), pp.329~333 (2016), 대한가정의학회
- Lan TY, "The use of hypnotics and mortality-a population-based retrospective cohort study", PLoS One, 10, pp.e0145271~ (2015)
- Armstrong TS, "Sleep-wake disturbance in patients with brain tumors", Neuro Oncol, 19, pp.323~335 (2017)
- Jeon MS, "Sleep disturbance of adults with a brain tumor and their family caregivers : a systematic review", Neuro Oncol, 19, pp.1035~1046 (2017)
- Yavas C, "Health-related quality of life in high-grade glioma patients : a prospective single-center study", Support Care Cancer, 20, pp.2315~2325 (2012)
- Min Cheol Chang, "The Effect of Hypnotics on Sleep Quality and Cognitive Function in Patients with Brain Tumors", 대한신경외과학회지, 63(2), pp.261~267 (2020), 대한신경외과학회
- Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- "MicroData Integrated Service (MDIS)"[URL]
- Greenblatt DJ, "Zolpidem for insomnia", Expert Opin Pharmacother, 13, pp.879~893 (2012)
- Yang BR, "Prescription of zolpidem and the risk of fatal motor vehicle collisions : a population-based, case-crossover study from South Korea", CNS Drugs, 32, pp.593~600 (2018)
- Donnelly K, "Benzodiazepines, Z-drugs and the risk of hip fracture : a systematic review and meta-analysis", PLoS One, 12, pp.e0174730~ (2017)
- Amerio A, "Carcinogenicity of psychotropic drugs : a systematic review of US Food and Drug Administration-required preclinical in vivo studies", Aust N Z J Psychiatry, 49, pp.686~696 (2015)
- Kao CH, "Relationship of zolpidem and cancer risk : a Taiwanese population-based cohort study", Mayo Clin Proc, 87, pp.430~436 (2012)
- Kripke DF, "Hypnotic drug risks of mortality, infection, depression, and cancer : but lack of benefit", F1000Res, 5, pp.918~ (2016)
- Jaussent I, "Hypnotics and mortality in an elderly general population : a 12-year prospective study", BMC Med, 11, pp.212~ (2013)